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Quality of life in patients with acute myelogenous leukemia in 
prolonged first complete remission after bone marrow transplantation
or autologous) or chemotherapy: a cross-sectional study of
the EORTC-GIMEMA AML 8A trial
vary from one study to another, they show generally a 
lower risk of relapse, and a longer disease-free survival 
A cross-sectional study of quality of life (QQL) was per- (DFS) after AlloBMT and ABMT than after ICC.
formed in 98 in continued first complete From 1986 to 1992, the EORTC and GIMEMA Leuke-
remission (CR) for 1-7.4 years inclusion in the mia Cooperative Groups prospectively compared
AML 8A trial which prospectively compared allogeneic three therapeutic options: patients with newly diagnosed 
bone marrow transplantation (AlloBMT), autologous AML were entered in the AML 8A trial, and, after the same
r
therapy
intensive consolidation chemo-
differenees between the 
were observed, on the basis of 
reports, with regard to somatic symptoms
s, headache), repeated 
physical functioning, role l’unc- 
and, above all, sexual func-
induction and intensive consolidation course, were
according to of a HLA-
a
donor or randomization, to AlloBMT, ABMT or 
ICC course. At a median follow-up time of 3.3
years, there was a significantly longer DFS in the AlloBMT
and ABMT (48%) arms than in the ICC arm (30%).5 
, the overall survival after CR was similar in the 
significant differences for over- three arms, patients relapsing after ICC being more easily
receiving an ABMT duringall physical condition, and overall quality of life. For all 
these parameters, the ranking was uniformly AlloBMT second CR.
than ABMT lower than chemotherapy. These dif- 
remain significant after adjustment for time 
between CR and OOL evaluation, sex or age.
The conclusions of this study were based on analyses
to the intention-to-treat princ In
addition, we have observed a significant difference with 
These results, confirming a higher risk of permanent regard to the short-term toxicity of the treatment actually
nt of QOL after BMT, may have an impact administered, the treatment-related mortality being 20, 10 
on medical decisions and warrant further studies, and 6% after AlloBMT, ABMT and second ICC, respect-
quality of life; acute myeloid leukemia; bone ively. Furthermore, the final results may also be hampered
m a m  nv transplantation
...................................... .....................
by long-term toxicity, especially due to the conditioning 
regimens, with or without total body irradiation (TBI), for
AlloBMT
Allogeneic bone marrow transplantation (AlloBMT), auto- city is also likely to induce psychosocial sequelae
logous bone marrow transplantation (ABMT), or intensive 
consolidation chemotherapy (ICC) are currently proposed 
for patients with acute myelogenous leukemia (AML) once 
they enter into complete remission (CR). The relative value 
of these three treatment options has been assessed by sev­
eral multkenter trials, patients being assigned to 
when an HLA-matehed sibling was available, 
and ICC were randomized.1 4 Although the results may
shown that qui of life
(QOL) might be more or 
AlloBMT,6 8 especially in
mar
case
impaired after
* I**/ ’on ic
We therefore, that
AlloBMT, ABMT
patients surviving in st CR.
QOI
0 0 1
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Vri
tun. Department of Menu
?. 751H1 Paris eedex 01, France
, Hotel-Dieu
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trials. Since QOL is a multidimensional concept including 
at least physical, psychological and social domains, one has 
to select multi-item instruments that meet the requirements
reliability for assessment of the
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various components of these domains.10 It is generally evaluation was performed from January 1993 to March
1995. All eligible patients received a set of questionnaires 
from their local investigator with a covering letter guaran-
assumed that self-report questionnaires are more reliable 
than proxy evaluations.11 Specific instruments may allow 
better evaluation of the impact of treatments, and are usu- teeing strict confidentiality and suggesting they contact a 
ally preferred to generic questionnaires. In addition, trans- locally appointed person in case of any problem. Medical
cultural problems must be adequately solved, in order to 
provide acceptable questionnaires to patients enrolled in 
international trials.12 We decided, therefore, to perform a 
cross-sectional study using the EORTC Quality of Life
information, especially that related to treatment side- 
effects, eg acute and chronic GVHD, was collected from 
the case report forms filled in by the responsible physicians. 
The patient self-administered questionnaires included a
Questionnaire (QLQ-C30) combined with, specific modules demographic questionnaire, the EORT QLQ-C30
designed to assess QOL after treatment of acute leukemia questionnaire, a Leukemia-BMT-specific module, a short
including BMT.
Patients and methods
Patients
Patients were eligible for the QOL study if they had been 
enrolled in the EORTC-GIMEMA AML 8A trial and were 
in continued first CR 1 year or more after completion of 
the treatment protocol. The main inclusion criteria in the 
trial were: a diagnosis o f AML in previously untreated 
patients, and absence of severe concomitant disease. 
Patients had to be more than 10 and less than 60 years old, 
but 25 patients (2.7%) were less than 15 and are not 
included in the present study. Of the 623 patients from 59 
centers who achieved CR after the induction regimen, 576 
received a first ICC. Of them 168 patients had an HLA 
identical sibling and 144 underwent an AlloBMT. Two 
hundred and fifty-four patients were randomized to ABMT 
or second ICC, which were completed in 95 and 104 
patients, respectively. Eighteen centers agreed to participate 
in the QOL study. Out of 155 patients from these centers
questionnaire on sexual functioning and fertility, and a 
questionnaire on patient perception of changes in the vari­
ous domains' of QOL (ie disease-related modifications).
The demographic questionnaire was derived from Hol- 
lingshead.13 Patients were also asked to indicate their mari­
tal and employment status both pre-diagnosis and at the 
present time.
The EORTC QLQ-C30 is a 30 item questionnaire which 
has been developed to cover a wide range of cancers, and 
is expected to be combined, for each study, with a disease- 
and/or treatment-specific module.14 It includes five multi­
item functional scales (Physical, Role, Cognitive, 
Emotional and Social functioning), several single item 
symptom measures and two items for global assessment of 
the overall physical condition and of QOL. Combination of 
the perceived Overall Physical Condition and Overall Qual­
ity of Life results in a Global Health Status score. This 
questionnaire meets acceptable standards for reliability, and 
its external validity has been checked in several hundreds 
of patients with lung cancer,14 and various types of can­
cer. 15 Its psychometric properties have been also evaluated 
in 125 adults surviving several years after BMT,16 with a
who were alive and in first CR for 1 year or more at the high internal consistency, and good reliability of the Role, 
time of study, 98 (63%) agreed to enter the QOL study: 35 Emotional and Cognitive functioning scales, and of the 
had an AlloBMT, 29 an ABMT, while 34 received only 
chemotherapy.
Global Health Status.
The Leukemia-BMT module (QLQ-LEU-BMT) is a 32 
item questionnaire which was designed on the basis of the
Methods of BMTMost
Informed consent was required for the QOL study, accord- especially those currently experienced by patients suffering 
ing to local rules. The allocated anti-leukemic treatments from GVHD. The psychometric properties of this module 
received by these patients are shown in Table 1. The QOL were analyzed in 388 patients entered into the present
Table 1 Treatment received by the 98 patients whose quality of life was assessed
No. o f  patients'
I « . , *  •  r *  -
35
29
34
Treatment
Allogeneic BMT 
Autologous BMT
Chemotherapy
No. o f  pa tien ts and  modality o f  treatment o f
allocation
HLA-identical sibling
28 randomization 
1 individual choice
17 ICC2a by randomization 
10 ICC2tt by individual choice
6 ICC jil onlyb 
1 salvage induction only4*
Total body irradiation  
No. o f  patients (%)
30 (86) 
20 (69)
0 (0)
"ICC, First intensive consolidation course, administered to all patients before assignment to AlloBMT or randomization to ABMT or ICC,. ICC-.: second 
intensive consolidation course.
’’These patients received chemotherapy but went off-study afterwards because of toxicity and/or refusal of further treatment.
EORTC-GIMEMA AML 8A trial and into the MRC AML
10 trial in the UK, and who were in CR for at least 1 year 
after completion of treatment.17 All 32 variables had indi­
vidual measures of sampling adequacy greater than 0.5. 
Item total correlations and Cronbach alpha coefficients
indicate good internal consistency, many items being 
grouped into two subscales (alpha coefficients 0.79 and
0.71), which appear to correspond to GVHD and 
infection, respectively.
Most items of the EORTC QLQ-C30 and the QLQ-LEU- 
BMT use a 4-point Likert scale from 1 (not at all) to 4 
(very much); overall physical condition and QOL were 
assessed by two 7-point Likert scales. In addition, the first 
seven items of the EORTC QLQ-C30 correspond to two 
Guttman scales with dichotomous response categories (yes 
or no).
Sexual disorders categorized according to the Diagnostic 
and Statistical Manual of Mental Disorder (DSM IV) were 
divided into problems of sexual drive (interest), sexual 
arousal, orgasm disorder and pain disorder (eg 
dyspareunia). Four study specific single-item questions 
asked about: (1) interest, (2) pleasure or satisfaction, 
(3) level of sexual activity and, (4) ability to engage in 
sexual intercourse since their leukemia treatment (ie 
increased, decreased or remained the same). Level of pain 
during sexual intercourse was also assessed by one item 
from the Leukemia-BMT module on a 4-point scale ranging 
from ‘not at all’ to ‘very much’, with a high score indicat­
ing more of a problem. Problems with fertility were 
assessed by study-specific items; patients were asked if 
their treatment had caused infertility and, in those indicat­
ing that it had, if they had been aware of the possibility of 
infertility at the time they were initially treated. The extent 
to which they were bothered by infertility was assessed by 
a 7-point rating scale ranging from ‘not at all’ to ‘very 
much’. Those who reported that they considered themselves 
rendered infertile by the treatment were asked if they were 
seeking a resolution to their infertility (eg adoption, arti­
ficial insemination by donor) and whether this had been 
successful.
Finally the questionnaire included a Disease-Related 
Modifications module, where patients were asked to evalu­
ate the changes induced by their disease and treatment on 
several domains, each covered by a single item (Energy, 
Mood, Intellectual Capacity, Family Life, Sexual Relation­
ship, Professional Life, Social Relationships, Leisure 
Activities and Quality of Life) with a 5 point scale of 
changes, ranging from ‘far worse’ to ‘far better’.
All these questionnaires, first developed in English, were 
translated into four European languages, French, Dutch, 
German, Italian, using a ‘forward-backward’ translation 
procedure. The reliability and validity of the EORTC QLQ- 
C30 is highly consistent across the three language-cultural 
groups studied: patients from English-speaking countries, 
Northern Europe and Southern Europe.14
Statistical methods
The usual x 2 test18 with the correction for continuity was 
used to test the balance of the initial characteristics among 
the treatment groups. The treatment differences regarding
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the QOL assessments (ie questions having as possible 
answers ordered categories) were tested using the Kruskal- 
Wallis test.19 The treatment comparisons leading to signifi­
cant differences were adjusted a posteriori by some vari­
ables having a possible impact on QOL. For this purpose, 
the following categorized variables were considered for the 
bi-variate analyses: sex (male vs female), age (<46 years 
vs 5=46 years), time from CR to the evaluation of QOL 
(<3 years, 3-4 years, 2*5 years). In case of ordered out­
comes (overall physical condition, quality of life or global 
health status -  see below), the stratified generalized Gehan- 
Wilcoxon test was used,19 whereas for all other ordered 
outcomes ( ‘not at all’, ‘a little’, ‘quite’, ‘much’ or ‘increa­
sed’, ‘same’, ‘decreased’ or ‘absent’, ‘present’), which were 
categorized as binary outcomes, the usual stratified x 2, test18 
was used. The Global Health Status score (grading from 
0 to 100) has been constructed from the Overall Physical 
Condition (1-7) and Overall Quality of Life (1-7) using 
the recommendations of the EORTC QOL Study Group.20 
The Goodman-Kruskal y  coefficient18 was used to measure 
the association between these two last scales. The Kendall’s 
t  test18 was used to measure the relationship between 
patient characteristics and the QOL items.
The planned sample size for the QOL study was 135 (45 
patients for each treatment group), as quite large differences 
between the treatment groups in terms of side-effects and 
QOL were expected. For instance, 30% difference (20 vs 
50%) between two treatment groups regarding the occur­
rence of side-effects requires a total of 90 patients 
(alpha = 0.05, beta = 0.20). However, due to administrative 
difficulties, the QOL assessment was implemented in only
18 out of 59 centers which participated in the AML 8A 
study. Therefore, the reported P  values should be con­
sidered cautiously: due to a relative low statistical power 
for detection of moderate treatment differences (range 20- 
30%), a result which yields a P  value >0.05 does not neces­
sarily mean that treatment impact on QOL is negligible. 
Conversely, due to the multiple comparisons, a P  value 
which is significant according to the classical rule (*50.05), 
does not necessarily mean that one may reject with full 
confidence the null hypothesis (no treatment difference), as 
the risk of a false positive result is high in this instance.
Results
The QOL study was performed at a median time of 53 
months after achievement of CR (range 12-89 months). 
The characteristics of the patients at the time of QOL evalu­
ation are shown in Table 2. There are slight differences 
between the three treatment groups, but only the difference 
for age at time of QOL evaluation was significant ( ^  test; 
P  = 0.05). This is explained by the fact that in some partici-
between ABMT and ICC was 60, whereas for AlloBMT 
the age limit of 45 was kept more often. The time elapsed 
between achievement of CR and evaluation of QOL was 
similar in the three treatment groups.
Patients included in the QOL study differed significantly 
from those who were not included, despite a similar DFS, 
with regards to age (a higher proportion above 46 years),
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Tabic 2 Patients’ characteristics at time of quality of life evaluation
Chemotherapy Autologous BMT A llogeneic BMT
No. of patients 34 29 35
Age
39 (20-51)median (range) 44 (19-65) 39 (22-65)
< 46  years (%) 56 65 83
Sex M/F 19/15 22/7 20/15
College graduate level or above (%) 32 31 29
Children (% with) 67 62 66
Living in big city (%) 48 45 28
Time from CR (months)
mean (s.e.) 50 (3.5) 56 (3.0) 48 (3.0)
median (range) 53 (12-81) 58 (28-89) 47 (19-79)
sex (more males), treatment completion (less premature with the QLQ-LEU-BMT. Table 4 shows those items for 
stop for toxicity or refusal), and proportion of randomized which differences were significant. For all those items 
patients (higher). However, they were not different with except two ( ‘taking pills/medicine or having seen a doctor 
regards to response to the first induction course, to balance during the last month’) the same ranking was observed 
between the randomized arms, and to incidence and grade regarding the frequency/severity of problems, being higher
in the AlloBMT group, compared with the ABMT group, 
both of which were higher than in the chemotherapy group. 
There was no significant difference between the treatment 
groups for the other items, although a trend with the same
of acute or chronic GVHD.
EO RTC QLQ-C30 questionnaire
Significant differences were observed between the treat- ranking was observed for chills, changes in appearance, eye 
ment groups for items evaluating physical functioning (‘Do dryness, and skin dryness (Table 5).
you have any trouble in taking a long walk?’) and role Some items of the QOL-LEU-BMT module correlated
functioning ( ‘Are you limited in any way in doing either significantly with the use (50 cases) or not (14 cases) of
your work or doing household jobs?’) (Table 3). Differ- TBI during the conditioning regimen for AlloBMT or
ences for the other items and scales assessing cognitive, ABMT (eye dryness: TBI (65%) vs no TBI (7%),
emotional and social functioning were not significant. The P  =  0.011, and headache: TBI (54%) vs no TBI (29%),
overall physical condition and quality of life were signifi P  -  0.05). On the other hand mouth sores con-elated with
cantly different between the three treatment groups with the occurrence and grade of chronic GVHD (no GVHD:
mean scores for AlloBMT <  ABMT <  chemotherapy. The 1/13 (8%); mild GVHD: 5/11 (45%), moderate/severe
resulting mean global health status on a 0-100 scale was GVHD: 6/11 (55%) P  = 0.01). 
therefore about 70 for AlloBMT, 75 for ABMT and 80 for
chemotherapy. Of note, a high association was observed 
between overall physical condition and overall QOL Sexuality-Fertility
(Goodman-Kruskal 7 = 0.70, P  <  0.001). More often (26 The main results for sexual functioning are shown in Table 
cases), patients rated their QOL as being higher than their 6. Sexual functioning was impaired in about one third of 
physical condition, than the reverse (15 cases).
Leukemia-BMT module
patients and was significantly more frequently impaired 
after AlloBMT (47-68% according to the items) than after 
ABMT (18-30%) or chemotherapy (15-22%). In addition, 
there was significantly more pain during sexual intercourse 
Although the somatic items included in the EORTC QLQ- in patients treated by both BMT procedures (Table 4). 
C30 were not significantly different between the treatment Patients who received TBI had impaired sexuality more 
groups (especially those relating to pain, nausea/vomiting, often than those not receiving TBI, but none of the com- 
lack of appetite, fatigue), several differences were observed parisons reached statistical significance, probably due to an
Table 3 Results of the EORTC Core questionnaire QLQ-C30
Chemotherapy Autologous BMT Allogeneic BMT P valueh
Trouble in taking a long walk (%) 23 28 49 0.05
Limited in doing work/household jobs (%) 18 34 49 0.026
Overall physical condition (1-7)“ 5.68 (0.21) 5.55 (0.26) 5.09 (0.16) 0.05
Overall quality of life (1-7)“ 6.0 (0.20) 5.41 (0.25) 5.29 (0.16) 0.017
Global health status (0-100)“ 80.6 (3.14) 74.7 (3.82) 70.1 (2.39) 0.03
"Mean score (s.e.) 
•’Kruskal-Wallis test.
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Table 4 Results (%) of Leukemia/BMT module
Chemotherapy Autologous BMT Allogeneic BMT P value“
Fever 9 7 31 0.012
Mouth sores 6 31 34 0.017
Dental problems 23 34 43 0.046
Cough 32 38 66 0.046
Hair loss 9 34 46 0.004
Headache 29 30 64 0.009
Pain during sexual intercourse 3 15 28 0.026
Any acute disease last month 15 30 45 0.024
See a doctor 41 33 64 0.048
Taking pills/medicine 50 33 76 0.004
“Kruskal-Wallis test.
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Table 5 Results (%) of the Leukemia/BMT module: items with no significant differences between treatment groups
Chemotherapy Autologous BMT Allogeneic BMT P value"
Chills 12 24 31 0.18h
Infection 26 24 34 0.56
Weight loss 15 10 26 0.26
Weight gain 29 28 26 0.86
Changed sense of taste 6 14 20 0.27
Changed sense of smell 6 17 11 0.36
Changes in appearance 9 14 31 0.05
Pain in abdomen 23 17 34 0.35
Mouth dryness 23 38 37 0.36
Eye dryness 15 21 35 0.10
Difficulty swallowing 6 10 15 0.48
Skin itching 29 34 43 0.44
Skin dryness 47 52 69 0.12
Abnormal hair growth 3 7 9 0.61
Stiff joints 35 43 51 0.37
Difficulty combing 6 3 6 0.88
Difficulty shaving/making up 0 3 6 0.38
Dizziness 29 17 26 0.54
Feeling cold 24 34 43 0.25
Flushes 30 22 27 0.87
Blurred vision 26 33 51 0.17
Hearing loss 15 37 21 0.11
Anal pain 3 4 0 0.57
Painful urination 9 0 0 0.07
Blood in urine 0 0 0
Admitted hospital last month 9 4 0 0.21
Treated
for cataract 0 7 3 0 .31
for hormonal disorders 16 19 27 o.4y
for joint problems 6 15 15 0.45
“Kruskal-Wallis test.
'’Data with a trend, and a ranking consistent with the other results, are labelled in bold characters.
Table 6 Results for sexual functioning (%)
Overall results (%) Decreased by treatment arm (%)
• i*  ■ ■  ■  1 '  r~U  ^  1  >1 ' .  , « * r r T % *  «  m i  m f  < * ,» 4  ♦ -  • -------- T  r<  •<. .  W I . J  .  -------- ---  -  -  -  —  i < \ J i  . . .  r  ‘ J S *  •• ,  r . i ' .  ■ ■ j. ».  *  j  -  . T
Increased Unchanged Decreased Chemotherapy ABMT AlloBMT P value"
Interest in sex 5 62 33 15 21 60 <0.001
Sexual activity 5 54 41 22 30 68 <0.001
Pleasure from sex 7 63 30 22 18 47 0.006
Ability to engage a sexual activity 3 62 35 2 1 29 53 0.014
“Kruskal-Wallis test.
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insufficient number of patients. Moreover, in the 35 patients 
who underwent AlloBMT, while the grade of acute GVHD
overall QOL, their present status with their pre-disease 
status. It can be seen that a wide range of perceived changes
seems to be associated with impaired sexuality, the grade was reported by patients, from ‘far worse’ to ‘far better’.
However, there was a trend in reporting the present status 
as being worse rather than better. When the three treatment 
groups were compared, a worsening was significantly more 
3% of patients who underwent AlloBMT, ABMT and frequently reported for leisure activities after AlloBMT or 
chemotherapy, respectively, while 3, 14 and 32% of them ABMT than after chemotherapy. There was also a trend
of chronic GVHD did not correlate with the results of the 
Sexuality module.
Treatment-related infertility was reported by 63, 48 and
in each treatment group declared themselves not to be infer- towards a worsening in AlloBMT and ABMT groups with
tile, and the remaining patients did not know their status regards to sexual relationship and mood. A worsening of 
in this regard (overall x 2; P  <  0.001). Most of the BMT the overall QOL was reported by 51% of patients who
underwent AlloBMT, vs 38% of ABMT patients and 30% 
of the ICC patients, but the difference was not
patients said they had been informed about the risk of infer­
tility at time of allocation of treatment (20, 62 and 83% in 
the three treatment groups, respectively). Only three statistically significant, 
patients looked for a resolution to their infertility, with only 
one male patient treated by ABMT being successful 
through the use of cryopreserved sperm. There was no Discussion 
significant difference between the three treatment groups
when patients were asked whether they were bothered by Our study shows some significant differences between
infertility.
Treatment adjustment and prognostic factors
AlloBMT, ABMT and chemotherapy, when assessing the 
long-term side-effects and multiple dimensions of QOL. 
These relate to somatic side-effects such as mouth sores, 
cough, headache, hair loss, and frequent acute episodes
After adjustment for sex as well as age at time of evalu- leading to referral to physicians. The most important long- 
ation, the evaluation of differences between the treatment term side-effects reported by patients were, however, infer-
groups led to similar results to those presented in Table 3. tility, decrease of sexual activity and loss of libido. These
In addition, the treatment comparisons yielded similar consequences of treatment consolidation of AML were 
results after adjustment for time interval between achieving more frequently observed after AlloBMT, and, to a lesser 
CR and evaluation of QOL. For most items, there was no degree, after ABMT, than after chemotherapy. The same
trend towards improvement as this time interval increased, ranking was observed, using the EORTC QOL core ques-
except for mouth sores which tended to be more frequently tionnaire, for physical and role functionings, with more
observed in patients studied within the first 3 years after limitations in physical and work performances in patients
achieving CR. Furthermore, sexual problems were more who had received AlloBMT. This ranking was consistent
frequently reported by females, who more often indicated for most comparisons, giving more strength to the statistical
a decrease of interest in sex (46 vs 25%, P — 0.021), and comparisons, despite the caveat emphasized in the Methods
in older patients (ie 46 years and above) who reported less section. Although our study was based on an empirical
sexual pleasure than younger patients (70 vs 25%, analysis through the main domains of QOL, most results
P =  0.016).
P erceived  changes by the patients
Table 7 shows the changes perceived by patients when
correspond to what was expected from the known toxicity 
of the compared treatment modalities.
Several studies have been published recently on various 
aspects of QOL in adults surviving after BMT/M;’If)-21~28 
Except for one prospective study,9 they were cross-
asked to compare, for the main domains of QOL, and the sectional analyses from 6-12 months and up to 18 years, io
Table 7 Patients perceived changes (%)
• ■ » i m i i » p p i | i w  ■ i  ^  ..............  ■
Overall changes (%) (% wor•se ned)
Far A bit No A bit Far Chemotherapy ABMT A lloBMT P"
------------- i . i i .  . . . . . _ v .  . . . . .  . . . . . . . . i * -  ............................................ ...... ,  — .............................. . * . * 1  n  r .  ................[ ------------------ - .  f  . * . «  •» .  v w h  .  .  . .  « . . .  » . ----------------------- - -  -  . . * * 1 1 -------------—
better better change worse worse
Energy 5 5 31 30 28 44 69
I S  n  ; r w  m i W I ,  --------
63 0.22
Mood 5 15 43 25 11 24 48 40 0.18”
Intellectual capacity 3 3 65 18 9 28 28 24 0.88
Family life 8 7 68 10 8 12 17 21 0.99
Sexual relationship 3 4 61 17 14 13 29 50 0.07
Professional life 8 10 31 30 21 39 55 59 0.45
Social relationship 5 13 54 18 9 18 28 34 0.83
Leisure activities 9 11 49 24 8 15 31 49 0.02
Overall quality of life 12 16 32 33 8 30 38 51 0.68
"Kruskal-Wallis test
'’Data with a marked trend, although not necessarily statistically significant, are labelled in bold characters.
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after completion o f BMT.
syngeneic
{plantation procedures per- ual patients to make a decision, after taking into consider-
AlloBMT, ation the relative risks of relapse and treatment-related mor- 
two studies tality. In addition, patient rating of their own QOL was
focused on ABM I, in patients mainly treated for lymphoid more frequently better than their rating of overall physical
maimnaneies.’y",° Usually
variety of diseases. Pew studies were intended to compare
22.2 . Qn|y wne was Specific for
publications included a condition and there was no significant change in the per
BMT and
ceived global post-treatment QOL. These might
AlloBMT
spective trials, 
evaluates specifically the
indicate that the majority of patients adapt their perception 
of QOL, despite post-treatment somatic sequelae, but could
lor patients included in two consecutive pro- also be related to a lack of sensitivity of global QOL scale
ir 4 * 4  n i t  *.  x  . 1 •  m !  .  t  i  I . l  . . .a.  . . .  i . y  i  1 * 1  *  •  1  ■ *  ' i  tiS, first which in picking up specific problems.
international
AML patients
Ul parti cip
8A trial coll
makes a sc
The most important difference between the treatment 
groups was related to sexual functioning and psychosexual
our module was
quite simple and brief, and deserves further validation, the
data indicate a greater impairment
AlloBMT and, to a lesser degree, after ABMT than after
CT. correlated with
Most of the previous publications have emphasized a
which
QOL
treated by AlloBMT
?.u
from BMT. Sexual dysfunction has been high- 
l the vast majority of patients lighted by two important studies dealing with problems in 
some emotional and social long-term survivors after AlloBMT.16,24 Surprisingly, other
authors have not found differences with regards to psycho-sion was
T and ABMT. However, several studies have 
pointed out the possibility of long-term physical, psycho­
logical or social problems after BMT. Permanent fatigue 
and lack of energy/stamina are frequently reported.6,7,16 
Cognitive dysfunction has been also observed,16 which 
might be related to the dose of TBI.32 Although most of
observed by Jenkins et til,K especially in patients with ante- sexual functioning in patients treated by AlloBMT or 
cedent psychiatric disorders, with no difference between CT.25,33 However, as shown by several other analyses
focused on both psychosexual, hormonal and fertility 
aspects34-38 sexual dysfunction is likely to occur in patients 
with sexual organ failure due to conditioning with intensive 
chemotherapy or radio-chemotherapy.39
One can hypothesize several factors to explain the higher 
frequency of sexual dysfunction after BMT -  especially 
these young adult patients return to work, have good social AlloBMT -  such as the use of TBI during conditioning, or
family/partner the occurrence of acute GVHD. We did not observe sig- 
al and marital prob- nificant correlations with these factors, perhaps due to the 
substantial pro- relatively limited number of patients in each group. Further
studies are required, to identify the etiological factors (eg 
impact of dosage in TBI on gonadal function). Of note, 
some predictive variables have already been reported to 
influence sexual satisfaction of long-term survivors such as 
a younger age at time of transplant, overall life satisfaction 
and satisfying relationship with spouse or partner.39 How­
ever, hormonal failure is likely to be the most important 
in BMT etiological factor, and along with infertility, represents an
important part of an eventual permanent impairment of
relationships
have re poi in
portion. i The risk of job discrimination and prob­
lems in obtaining insurance have also been emphasized.26
Comparison of with alternative treatments 
Lesko et a l ,22 Litwins et a l,23yielded controversial results: 
and Wellisch e t a!1*1 failed to observe differences between
T i CT with regard to various ains of QOL
whereas Altmaier et a l 'H found more physical
unemployment, financial and marital pr 
than in matched CT patients.’8 O g;% t *se
were based on small patient numbers, and, except for one,25 QOL after BMT
were performed outside prospective trials.
Despite the limited number of patients in each treatment 
rroup, our results indicate differences which consistently
long-term side-effects such as cryopreservation of
aeemenl. For othersperm or ova, and hormonal 
patients, who, for individual preference, would not accept
e < ABMT <  CT, most the risk of these permanent side-effects, another
CT patients being treated with high-dose Ara-C consoli 
dation courses. These differences were found for physica
r
il
activities, and, 
especially, for sexual functioning. Probably as a conse­
quence, using the EORTC-QLQ 
nificant differences with the same ranking
between the three treatment modalities for oven
solution is to give preference to ICC consolidation during 
first CR, and to choose BMT only as a salvage treatment 
in case of relapse.
Some studies have identified, through multivariate analy­
ses, variables which might represent risk factors for impair-
cation level
QOL after BMT, especially TBI, GVHD, age, e
role retention, and social -------40 If
e ondilion, overall QOl
of relative weight ing  of
severe (ICC) and
global health confirmed, these factors would indicate which appropriate
medical and psychosocial measures are needed to preserve 
or restore the QOL during and after such intensive treat- 
more severe ments. For example, avoiding TBI during conditioning regi-
(AlloBMT) might appear small (10% for the global health men for AlloBMT and ABMT might be
not importi to at CT prevails.
re fore some caution is necessary when helping
since in AML a pure chemotherapy regimen seems to yield 
equivalent DFS as a radio-chemotherapy regimen.41
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A final problem, essential when considering the long­
term adverse effects on QOL of these treatments, is the 
chance of a progressive improvement over time. The lack 
of prospective, longitudinal analyses precludes any firm 
conclusion in this respect. Most previous studies have tried 
to approach this question through multivariate analyses, 
using the time from CR or completion of treatment as a 
covariate. This has resulted in controversial results, some 
studies showing no change over time6,23 with others indicat­
ing a progressive late improvement.16’2125 In the present 
series, only the mouth sores which correlated with chronic
GVHD, improved significantly the first 3 years.
Further longitudinal studies should be proposed, in order 
to evaluate these changes over time, and to adapt treatment 
and support according to needs.
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